- For Print
- May 17, 2013
¾«¶«Ó°Òµ. (Headquarters: Tokyo, President and CEO: Haruo Naito, “Eisai”) announced today that a series of abstracts highlighting new study results on Halaven® (generic name: eribulin mesylate; non-taxane microtubule dynamics inhibitor) and lenvatinib (generic name; VEGF receptor tyrosine kinase inhibitor and multikinase inhibitor) will be presented during the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago, the United States, from May 31 to June 4, 2013.
This year’s ASCO meeting will include presentations highlighting the results of subgroup analyses and quality of life (QOL) research into a head-to-head study of Halaven versus capecitabine (Study 301) that was conducted in 1,102 patients with locally advanced or metastatic breast cancer, as well as the results of Phase II studies of lenvatinib in patients with endometrial cancer and melanoma.
¾«¶«Ó°Òµpositions oncology as a key franchise area. The company will continue to create innovation in the development of new drugs based on cutting-edge cancer research, and in doing so seeks to make further contributions to address the diversified needs of, and increase the benefits provided to, patients and their families as well as healthcare providers.
Major ¾«¶«Ó°Òµabstracts accepted for presentation at this year’s ASCO meeting include:
Product | Abstract title and scheduled presentation date and time (local time) |
---|---|
Eribulin Mesylate Abstract No: 1049 |
A Phase III, open-label, randomized study of eribulin mesylate versus capecitabine |
Eribulin Mesylate Abstract No: 1050 |
Quality of life (QoL) in patients (pts) with locally advanced or metastatic breast cancer (MBC) |
Eribulin Mesylate Abstract No: 1055 |
Quality of life (QoL) and content validity in objective tumor response. |
Eribulin Mesylate Abstract No: 563 |
Eribulin mesylate (Erib) plus capecitabine (X) for adjuvant treatment in |
Lenvatinib Abstract No: 5520 |
A phase II trial of lenvatinib in patients with advanced or recurrent endometrial cancer: |
Lenvatinib Abstract No: 5591 |
Analysis of plasma biomarker and tumor genetic alterations from a phase II trial |
Lenvatinib Abstract No: 9026 |
A phase II study of the multitargeted kinase inhibitor lenvatinib in patients |
Lenvatinib Abstract No: 9058 |
Analysis of serum biomarkers and tumor genetic alterations from phase II study |
Lenvatinib |
Lenvatinib combined with dacarbazine versus dacarbazine alone |
Media Inquiries:
Public Relations Department,
¾«¶«Ó°Òµ.
+81-(0)3-3817-5120